NEW YORK (GenomeWeb News) – The drug discovery company Chemizon has struck a strategic partnership with the clinical research company Crown Biosciences to offer a number of drug research capabilities, including proteomics and biomarker services, Chemizon said today.
 
Chemizon, which is a division of Optomagic, also said it has made an investment in CrownBio of an undisclosed amount through a private equity fund. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.